Moreover, no significant differences in the MMP9 serum levels were found between anti-Jo1 positive ILD patients and anti-Jo1 positive non-ILD myositis patients (p = 0.061) or between survival and deceased group (p = 0.443). Here, MMP9 is linked to interstitial lung disease.